Buy & Sell Clorox Co (CLX) – Clorox Co Price Today
Aura AI Summary
Key Stats
- $11.50BMarket Cap
- Consumer StaplesSector
- -32.27%3M Drawdown
- $14.80BEnterprise Value
- 5.22%Dividend Yield
- 100 daysTypical Hold Time
Clorox Co (CLX) is currently valued at a market capitalization of $11.50B, with an enterprise value of $14.80B. Over the past 52 weeks, Clorox Co has traded between a low of $86.12 and a high of $131.88, highlighting its annual price range. Over the past three months, Clorox Co has recorded a drawdown of -32.27%, reflecting recent price volatility. Clorox Co offers a dividend yield of 5.22%, with the most recent dividend of $1.24 paid on 22 Apr 26. On average, investors hold Clorox Co for approximately 100 days, indicating typical investor behavior on the platform.
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Most Recent News
Enhanced Games debuts in Las Vegas with boosted athletes and a TikTok-friendly sports format
Enhanced Games will hold its first competition in Las Vegas featuring 50 enhanced athletes, including Olympic and world champions, competing in a new sports format designed for digital and social media viewing. The event combines track, pool, and wei...

Phibro Animal Health CEO sold 21,120 shares worth $1.2 million
Phibro Animal Health's CEO recently sold 21,120 shares of the company, generating proceeds of approximately $1.2 million. This insider sale might indicate the CEO's personal financial planning or a strategic move, but it could also raise questions am...

Patient Square buys 210,000 shares of Nektar Pharmaceuticals, signaling strong confidence.
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
